(CDAX, Financial Services, MUX GR)



D.m.		Value Indicators:		Warburg ESG Risk Score:	2.8	Description:	
Buy		SotP:	33.67	ESG Score (MSCI based):	3.0	Mutares is a PE group which	
0.4.00				Balance Sheet Score:	3.3	specializes on turnaround and	
EUR <b>34.00</b>				Market Liquidity Score:	2.0	restructuring cases	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2023e
		Market cap:	581	Freefloat	65.10 %	Beta:	1.3
Price	EUR 28.25	No. of shares (m):	21	Robin Laik (CEO)	25.01 %	Price / Book:	0.7 x
Upside	20.4 %	EV:	1,163	Elber GmbH	10.10 %	Equity Ratio:	25 %
		Freefloat MC:	378			Net Fin. Debt / EBITDA:	2.9 x
		Ø Trad. Vol. (30d):	878.33 th			Net Debt / EBITDA:	3.4 x

### First Glance: Mid-term target upgraded at CMD

Mutares updated and upgraded its mid-term target at its CMD. The former mid-term target was aiming for consolidated group sales of EUR 7bn by FY 25 and corresponding net income of EUR 125-150m, which is around the estimated 2% holding net income profitability. The mid-term target has now been pushed forward to FY 28 and, by then, Mutares is expecting consolidated group sales of EUR 10bn and a corresponding holding net income of EUR 200m. This basically increases the result achieved in FY 19 ten-fold in less than 10 years.

Mutares' net income is generated by three profit streams, a) consultant income for the restructuring of newly acquired turnaround cases b) equity upstream, which is distribution of capital or earnings from businesses turned around and c) exit gains. Holding sales reflect consulting revenues. These are likely to exceed EUR 100m by FY23 and are poised to grow further as Mutares expands into the US and China. Equity distributions and exit gains are connected as e.g. a business with an unused cash position after turnaround could either distribute the cash or achieve a higher exit gain.

In September, Mutares finalized the exit of SMP, which leads to a cash contribution of EUR 150m or more than EUR 7 per share. This has been the biggest exit so far and, with these proceeds, Mutares will now show a net income margin of around 2% for five years in a row, i.e. the EPS is likely to surpass EUR 5.0 per share. As a result of the exit, Mutares has raised the base dividend to be paid to EUR 2.0 which is a 7% yield on a current peak share-prices.

We regard Mutares as well positioned to continue to achieve the net income margin of 2% going forward. In the past two days, two more buyside transactions have been announced and management indicated that it is close to announcing more transactions. The portfolio remains well filled and keep in mind that the more sizable transactions of the past are just entering the harvesting phase.

Our current forecast for the holding net income mainly accounts for the consulting profit and equity distributions consisting of distributable net income. Looking at Lapeyre, which still has a cash position close to EUR 200m after the turnaround and a considerable asset (real estate) portfolio as well, our estimates reflect neither a possible exit nor a distribution of the cash or assets even though it is possible and likely from the end of FY 24 onwards. We regard this as probably the most conservative approach to forecasting. Using Mutares' targeted ROIC of 7-10x and its current invested capital of EUR 270m or even only a high single-digit multiple on the implied EPS guidance grants generous triple-digit percentage upsides from current valuations.


At this point, we reiterate our Buy recommendation as well as our price target of EUR 34. Post the release of Q3 figures due November 9, which should include the exit of SMP, we will update our model and include the recent buy-side transactions as well.



Trailing 12 months:	52.5 %
Company events: 07.11.23	Q3

FY End: 31.12. in EUR m	CAGR (22-25e)	2019	2020	2021	2022	2023e	2024e	2025e
Sales Change Sales yoy	14.3 %	1,016 17.4 %	1,584 55.9 %	2,504 58.1 %	3,752 49.8 %	5,089 35.6 %	5,490 7.9 %	5,595 1.9 %
Sales Holding	26.7 %	19	32	50	71	109	130	145
Chg yoy		83.0 %	65.0 %	58.2 %	40.9 %	53.6 %	18.6 %	11.8 %
Portfolio equity distributions		22	35	14	69	22	37	55
Portfolio income		41	66	65	140	131	167	200
Exit gains	-	0	0	58	4	114	0	0
Net income holding		23	33	50	71	125	44	69
Net income margin holding		116.6 %	104.7 %	98.2 %	100.3 %	114.8 %	34.0 %	47.5 %
EBITDA adj.		7	-29	-41	-33	71	168	243
Net income	-	21	27	449	-7	-50	-69	2
Net income adj.		23	33	50	71	125	44	69
EPS adj.		1.48	2.20	3.00	3.46	6.08	2.13	3.33
P / E adj.		6.8 x	5.1 x	7.4 x	5.6 x	4.6 x	13.3 x	7.1 x
DPS	0.0 %	1.00	1.50	1.50	2.00	2.00	2.00	2.00
Dividend Yield		10.0 %	13.3 %	6.8 %	10.4 %	7.1 %	7.1 %	8.5 %
EPS		1.37	1.79	27.18	-0.33	-2.43	-3.35	0.12
P/E		7.3 x	6.3 x	0.8 x	n.a.	n.a.	n.a.	196.7 x
Guidance: Group sales EUR 4.8-5.4bn, net income holding EUR 92-112m								





## **Company Background**


- Mutares was co-founded in 2008 by CEO Robin Laik.
- Mutares invests in small/midcap (sales 50-500m) companies in special situations and manages the turnaround with its own consultants
- Consolidated sales increased from EUR 60m in 2010 to above EUR 2.5bn in 2021 as the company made more than 80 transactions
- Mutares has consistently paid a dividend and targets a base dividend of EUR 1.0. The dividend yield has exceeded 5% over the past five years.
- The company issued a bond and raised equity of combined 180m in the last two years to accelerate growth as the Covid pandemic gave rise to unique investment opportunities

## **Competitive Quality**

- With more than 100consultants, who are turnaround specialists, at the end of 2020, Mutares has established a European network of offices enabling the generation of synergies across its portfolio holdings.
- European small-midcap special situations management is a niche market with limited competition
- Management and board members hold significant stakes of outstanding shares
- For FY 23 Mutares targets annual consolidated sales of EUR 5bn, which translates into a holding profit of EUR 100m respectively a net margin of 1.8-2.2%



Source: Warburg Research



Source: Warburg Research



Sum of the parts								
Net Asset Value			all Warburg R	esearch estimat	es			
Company	exit date	sales Wre	EBITDA margin	EBITDA / EBIT	Exit mutiple	EV	probability	NPV
Amaneos	2026	1.200	6%	72,0	6,0	432	25%	81,4
Arriva	2027	400	7%	28,0	6,0	168	10%	11,5
Asteri / Palmia	2026	150	5%	7,5	6,0	45	10%	3,4
Celcim	2026	55	9%	5,0	7,0	35	35%	9,1
Donges Group	2023	200	8%	16,0	7,0	112	35%	39,2
Exi / Six	2026	75	6%	4,5	8,0	36	25%	6,8
Fasana	2026	65	7%	4,6	8,0	36	10%	2,7
Frigoscandia	2026	365	6%	21,9	7,0	153	25%	28,9
Ganter	2026	80	7%	5,6	7,0	39	25%	7,4
Gemini / Adcoms	2024	100	8%	8,0	8,0	64	10%	5,8
Guascor Energy	2027	100	8%	8,0	7,0	56	10%	3,8
inovis group (Valmet Automotive)	2026	50	5%	2,5	5,0	13	10%	0,9
keeeper	2024	90	11%	9,9	9,0	89	25%	20,3
Kico Group	2026	220	10%	22,0	6,0	132	25%	24,9
La Rochette	2026	160	9%	14,4	7,0	101	35%	26,6
Lapyere	2026	750	8%	60,0	7,0	570	10%	42,9
Metals Group	2027	600	8%	48,0	7,0	336	10%	23,0
NEWBalcke-Dürr	2026	340	6%	20,4	6,0	122	25%	23,0
Peugeot Motor	2028	140	7%	9,8	6,0	59	10%	1,8
Plati	2026	40	8%	3,0	7,0	21	25%	4,0
Repartim (Carglas Maison)	2026	40	7%	2,8	7,0	20	25%	3,0
Sabo	2026	30	10%	3,0	8,0	24	50%	9,0
SMP (Special melted products)	2023	140	9%	12,6	7,0	88	10%	150,0
Steyr Motors	2026	30	7%	2,1	7,0	15	10%	1,1
Terranor (Nordic Road Services)	2024	215	9%	19,4	7,0	135	35%	43,1
VALTI (Vallourec Bearing Tubes)	2027	50	7%	3,5	7,0	25	10%	1,7
Valor	2027	200	8%	16,0	6,0	96	10%	6,6
					-			<b></b>
					_	2493,6		563,

2025e
144,8
26,1
9,9%
263
55,0
9,9%
555

Enterprise Value / CF	145,9	60,3	818,3
Discounted values	145,9	54,9	677,4
Discounted sum EV/CF	878,2		
Debt	100,0		
Cash	12,5		
Other debt like items	98,3		
Equity Value	692		
Number of shares outstanding	20,6		
Fair value per share (EUR)	33,7		

As debt we deduct the outstanding bond and given guarantees

# Mutares



Valuation							
	2019	2020	2021	2022	2023e	2024e	2025e
Price / Book	0.8 x	0.9 x	0.5 x	0.6 x	0.7 x	0.8 x	0.6 x
Book value per share ex intangibles	8.17	7.38	28.56	27.56	33.31	30.38	30.92
EV / Sales	0.4 x	0.3 x	0.3 x	0.3 x	0.2 x	0.2 x	0.2 x
EV / EBITDA	4.6 x	3.6 x	1.5 x	6.0 x	6.8 x	7.1 x	4.2 x
EV / EBIT	14.0 x	12.5 x	2.0 x	n.a.	n.a.	n.a.	52.3 x
EV / EBIT adj.*	14.0 x	n.a.	n.a.	7.8 x	n.a.	n.a.	52.3 x
P/FCF	n.a.	n.a.	n.a.	n.a.	n.a.	28.6 x	4.2 x
P/E	7.3 x	6.3 x	0.8 x	n.a.	n.a.	n.a.	196.7 x
P / E adj.*	6.8 x	5.1 x	7.4 x	5.6 x	4.6 x	13.3 x	7.1 x
Dividend Yield	10.0 %	13.3 %	6.8 %	10.4 %	7.1 %	7.1 %	8.5 %
FCF Potential Yield (on market EV)	21.5 %	28.2 %	66.4 %	20.0 %	14.6 %	14.1 %	23.9 %
*Adjustments made for: -							


Company Specific Items							
	2019	2020	2021	2022	2023e	2024e	2025e
Sales Holding	19	32	50	71	109	130	145
Portfolio equity distributions	22	35	14	69	22	37	55
Exit gains	0	0	58	4	114	0	0
Net income holding	23	33	50	71	125	44	69
adj. EBITDA holding	1	5	-18	-7	2	21	29
Income investments holding	22	35	71	72	136	37	55
Chg yoy	83.0 %	65.0 %	58.2 %	40.9 %	53.6 %	18.6 %	11.8 %
Net income margin holding	116.6 %	104.7 %	98.2 %	100.3 %	114.8 %	34.0 %	47.5 %
Consulting income	-1	4	7	13	20	23	26
Portfolio income	41	66	65	140	131	167	200



Consolidated profit & loss							
In EUR m	2019	2020	2021	2022	2023e	2024e	2025
Sales	1,016	1,584	2,504	3,752	5,089	5,490	5,59
Change Sales yoy	17.4 %	55.9 %	58.1 %	49.8 %	35.6 %	7.9 %	1.9 %
Increase / decrease in inventory	-4	-23	7	-16	0	0	(
Total Sales	1,012	1,561	2,511	3,735	5,089	5,490	5,595
Material expenses	623	975	1,580	2,399	3,257	3,514	3,581
Gross profit	389	586	931	1,337	1,832	1,977	2,014
Gross profit margin	38.3 %	37.0 %	37.2 %	35.6 %	36.0 %	36.0 %	36.0 %
Personnel expenses	292	424	660	910	1,476	1,592	1,623
Other operating income	119	241	770	356	597	644	656
Other operating expenses	138	261	474	601	782	860	804
Infrequent items	0	0	0	0	0	0	(
BITDA	79	143	567	181	171	168	243
Margin	7.8 %	9.0 %	22.6 %	4.8 %	3.4 %	3.1 %	4.3 %
Depreciation of fixed assets	53	102	119	185	204	220	224
BITA	26	41	448	-3	-33	-52	19
Amortisation of intangible assets	0	0	0	0	0	0	C
Goodwill amortisation	0	0	0	0	0	0	(
BIT	26	41	448	-3	-33	-52	19
Margin	2.6 %	2.6 %	17.9 %	-0.1 %	-0.6 %	-0.9 %	0.3 %
EBIT adj.	26	-130	-160	140	-33	-52	19
nterest income	2	4	9	15	1	1	1
nterest expenses	11	28	27	68	18	18	18
Other financial income (loss)	0	0	0	0	0	0	C
EBT '	17	17	429	-56	-50	-69	2
Margin	1.6 %	1.1 %	17.1 %	-1.5 %	-1.0 %	-1.3 %	0.0 %
Fotal taxes	0	-3	-14	-36	0	0	C
Net income from continuing operations	17	20	443	-21	-50	-69	2
ncome from discontinued operations (net of tax)	0	0	0	0	0	0	0
Net income before minorities	17	20	443	-21	-50	-69	2
Minority interest	-4	-7	-7	-14	0	0	C
Net income	21	27	449	-7	-50	-69	2
Margin	2.0 %	1.7 %	17.9 %	-0.2 %	-1.0 %	-1.3 %	0.0 %
Net income adj.	23	33	50	71	125	44	69
Number of shares, average	15	15	17	21	21	21	21
EPS	1.37	1.79	27.18	-0.33	-2.43	-3.35	0.12
EPS adj.	1.48	2.20	3.00	3.46	6.08	2.13	3.33
*Adjustments made for:							

Guidance: Group sales EUR 4.8-5.4bn, net income holding EUR 92-112m


Financial Ratios							
	2019	2020	2021	2022	2023e	2024e	2025e
Total Operating Costs / Sales	91.8 %	89.5 %	77.6 %	94.7 %	96.6 %	96.9 %	95.7 %
Operating Leverage	2.0 x	1.0 x	17.0 x	n.a.	26.2 x	7.3 x	n.a.
EBITDA / Interest expenses	7.2 x	5.1 x	20.8 x	2.7 x	9.5 x	9.3 x	13.5 x
Tax rate (EBT)	0.0 %	-16.6 %	-3.2 %	62.8 %	0.0 %	0.0 %	0.0 %
Dividend Payout Ratio	91.2 %	115.6 %	5.6 %	n.m.	n.m.	n.m.	1684.6 %
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.





Consolidated balance sheet							
In EUR m	2019	2020	2021	2022	2023e	2024e	2025
Assets							
Goodwill and other intangible assets	59	76	134	144	144	144	144
thereof other intangible assets	59	76	134	144	144	144	144
thereof Goodwill	0	0	0	0	0	0	(
Property, plant and equipment	176	243	557	764	645	510	370
Financial assets	17	9	74	46	46	46	46
Other long-term assets	123	150	324	398	398	398	398
Fixed assets	375	478	1,088	1,352	1,233	1,098	959
Inventories	134	204	423	561	727	784	799
Accounts receivable	172	295	342	458	621	670	683
Liquid assets	80	145	255	246	372	351	425
Other short-term assets	88	206	452	412	412	412	412
Current assets	474	850	1,472	1,677	2,133	2,218	2,320
Total Assets	849	1,327	2,560	3,030	3,366	3,316	3,278
Liabilities and shareholders' equity							
Subscribed capital	15	15	21	21	21	21	2
Capital reserve	37	38	134	135	135	135	135
Retained earnings	135	144	566	527	435	325	286
Other equity components	-2	-7	1	31	241	291	34
Shareholders' equity	185	190	721	713	831	771	782
Minority interest	23	17	15	1	1	1	
Total equity	208	207	736	714	833	772	783
Provisions	138	210	326	332	262	192	122
thereof provisions for pensions and similar obligations	87	116	153	94	94	94	94
Financial liabilities (total)	208	374	610	841	860	860	860
Short-term financial liabilities	41	57	69	136	136	136	136
Accounts payable	195	319	525	754	1,022	1,103	1,124
Other liabilities	100	217	363	389	389	389	389
Liabilities	640	1,120	1,824	2,316	2,533	2,544	2,495
Total liabilities and shareholders' equity	849	1,327	2,560	3,030	3,366	3,316	3,278

Financial Ratios							
	2019	2020	2021	2022	2023e	2024e	2025e
Efficiency of Capital Employment							
Operating Assets Turnover	3.5 x	3.8 x	3.1 x	3.6 x	5.2 x	6.4 x	7.7 x
Capital Employed Turnover	2.4 x	2.9 x	2.0 x	2.7 x	3.6 x	4.0 x	4.3 x
ROA	5.5 %	5.7 %	41.3 %	-0.5 %	-4.1 %	-6.3 %	0.3 %
Return on Capital							
ROCE (NOPAT)	7.5 %	9.8 %	51.4 %	n.a.	n.a.	n.a.	1.4 %
ROE	11.4 %	14.4 %	98.6 %	-0.9 %	-6.5 %	-8.6 %	0.3 %
Adj. ROE	12.3 %	17.8 %	10.9 %	9.9 %	16.2 %	5.5 %	8.9 %
Balance sheet quality							
Net Debt	215	345	508	689	583	603	530
Net Financial Debt	128	228	355	595	488	509	435
Net Gearing	103.5 %	166.3 %	69.0 %	96.6 %	70.0 %	78.1 %	67.6 %
Net Fin. Debt / EBITDA	161.7 %	160.1 %	62.6 %	328.0 %	286.3 %	303.9 %	178.9 %
Book Value / Share	12.0	12.3	35.1	34.5	40.3	37.4	37.9
Book value per share ex intangibles	8.2	7.4	28.6	27.6	33.3	30.4	30.9




Source: Warburg Research Source: Warburg Research

Source: Warburg Research



Consolidated cash flow statement							
In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Net income	17	20	443	-21	-50	-69	2
Depreciation of fixed assets	53	102	119	185	204	220	224
Amortisation of goodwill	0	0	0	0	0	0	0
Amortisation of intangible assets	0	0	0	0	0	0	0
Increase/decrease in long-term provisions	-15	7	-19	-59	0	0	0
Other non-cash income and expenses	-118	-243	-705	-100	0	0	0
Cash Flow before NWC change	-63	-115	-163	5	154	151	226
Increase / decrease in inventory	20	17	-22	-138	-166	-57	-15
Increase / decrease in accounts receivable	34	7	43	-117	-163	-49	-13
Increase / decrease in accounts payable	-2	48	38	228	269	81	21
Increase / decrease in other working capital positions	0	0	0	0	-20	-20	-20
Increase / decrease in working capital (total)	53	72	59	-26	-81	-46	-27
Net cash provided by operating activities [1]	-11	-43	-104	-21	73	105	199
Investments in intangible assets	0	0	0	0	0	0	0
Investments in property, plant and equipment	0	-29	-48	-84	-84	-84	-84
Payments for acquisitions	33	79	189	110	10	0	0
Financial investments	0	1	1	2	0	0	0
Income from asset disposals	23	1	33	46	150	0	0
Net cash provided by investing activities [2]	44	51	172	73	76	-84	-84
Change in financial liabilities	0	104	236	232	19	0	0
Dividends paid	-15	-15	-25	-31	-41	-41	-41
Purchase of own shares	0	-3	0	0	0	0	0
Capital measures	0	0	0	0	0	0	0
Other	-47	-29	0	0	0	0	0
Net cash provided by financing activities [3]	-62	58	211	201	-22	-41	-41
Change in liquid funds [1]+[2]+[3]	-29	66	280	253	126	-21	74
Effects of exchange-rate changes on cash	0	-1	0	0	0	0	0
Cash and cash equivalent at end of period	80	145	425	508	372	351	425

Financial Ratios							
	2019	2020	2021	2022	2023e	2024e	2025e
Cash Flow							
FCF	-21	-73	-154	-105	-12	20	115
Free Cash Flow / Sales	-2.1 %	-4.6 %	-6.2 %	-2.8 %	-0.2 %	0.4 %	2.1 %
Free Cash Flow Potential	79	146	580	217	171	168	243
Free Cash Flow / Net Profit	-102.9 %	-269.0 %	-34.3 %	1547.1 %	23.8 %	-29.5 %	4695.7 %
Interest Received / Avg. Cash	1.6 %	3.5 %	4.2 %	6.0 %	0.3 %	0.3 %	0.3 %
Interest Paid / Avg. Debt	6.5 %	9.7 %	5.5 %	9.4 %	2.1 %	2.1 %	2.1 %
Management of Funds							
Investment ratio	0.0 %	1.8 %	1.9 %	2.2 %	1.7 %	1.5 %	1.5 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	0.0 %	28.3 %	40.0 %	45.7 %	41.5 %	38.4 %	37.7 %
Avg. Working Capital / Sales	11.4 %	9.2 %	8.4 %	6.7 %	5.8 %	6.2 %	6.4 %
Trade Debtors / Trade Creditors	88.5 %	92.5 %	65.0 %	60.8 %	60.8 %	60.8 %	60.8 %
Inventory Turnover	4.6 x	4.8 x	3.7 x	4.3 x	4.5 x	4.5 x	4.5 x
Receivables collection period (days)	62	68	50	45	45	45	45
Payables payment period (days)	114	119	121	115	115	115	115
Cash conversion cycle (Days)	26	25	26	15	11	11	12





#### **LEGAL DISCLAIMER**

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

#### **COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

# DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <a href="http://www.mmwarburg.de/disclaimer/disclaimer/disclaimer.htm#Valuation">http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</a>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

#### SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



#### Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

# Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5**% of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or**investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)		
Mutares	5	https://www.mmwarburg.com/disclaimer/disclaimer en/DE000A2NB650.htm		



#### INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING


Rating	Number of stocks	% of Universe
Buy	157	74
Hold	44	21
Sell	6	3
Rating suspended	4	2
Total	211	100

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	44	86
Hold	5	10
Sell	0	0
Rating suspended	2	4
Total	51	100

#### PRICE AND RATING HISTORY MUTARES AS OF 13.10.2023



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES						
Matthias Rode	+49 40 3282-2678					
Head of Equities	mrode@mmwarburg.com					
RESEARCH						
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	<b>Hannes Müller</b> Software, IT	+49 40 309537-255 hmueller@warburg-research.com			
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com			
Stefan Augustin	+49 40 309537-168	Malte Schaumann	+49 40 309537-170			
Cap. Goods, Engineering	saugustin@warburg-research.com	Technology	mschaumann@warburg-research.com			
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com			
Christian Cohrs	+49 40 309537-175	Simon Stippig	+49 40 309537-265			
Industrials & Transportation	ccohrs@warburg-research.com	Real Estate, Telco	sstippig@warburg-research.com			
<b>Dr. Christian Ehmann</b> BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com			
Felix Ellmann	+49 40 309537-120	Robert-Jan van der Horst	+49 40 309537-290			
Software, IT	fellmann@warburg-research.com	Technology	rvanderhorst@warburg-research.com			
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com			
Marius Fuhrberg	+49 40 309537-185	Conward, 11	awon@warburg-research.com			
Financial Services	mfuhrberg@warburg-research.com					
Fabio Hölscher Automobiles, Car Suppliers	+49 40 309537-240 fhoelscher@warburg-research.com					
Philipp Kaiser	+49 40 309537-260					
Real Estate, Construction	pkaiser@warburg-research.com					
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com					
INSTITUTIONAL EQUI						
Marc Niemann	+49 40 3282-2660	Rudolf Alexander Michaelis	+49 40 3282-2649			
Head of Equity Sales, Germany	mniemann@mmwarburg.com	Germany	rmichaelis@mmwarburg.com			
Tim Beckmann	+49 40 3282-2665	Roman Alexander Niklas	+49 69 5050-7412			
United Kingdom  Lea Bogdanova	tbeckmann@mmwarburg.com +49 69 5050-7411	Switzerland	rniklas@mmwarburg.com			
United Kingdom, Ireland	lbogdanova@mmwarburg.com					
Jens Buchmüller	+49 69 5050-7415	Antonia Möller	+49 69 5050-7417			
Scandinavia, Austria  Matthias Fritsch	jbuchmueller@mmwarburg.com +49 40 3282-2696	Roadshow/Marketing  Charlotte Wernicke	amoeller@mmwarburg.com +49 40 3282-2669			
United Kingdom	mfritsch@mmwarburg.com	Roadshow/Marketing	cwernicke@mmwarburg.com			
Maximilian Martin	+49 69 5050-7413	Juliane Niemann	+49 40 3282-2694			
Austria, Poland	mmartin@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com			
SALES TRADING		DESIGNATED SPONSOR	ING			
Oliver Merckel	+49 40 3282-2634	Marcel Magiera	+49 40 3282-2662			
Head of Sales Trading  Rico Müller	omerckel@mmwarburg.com +49 40 3282-2685	Designated Sponsoring Sebastian Schulz	mmagiera@mmwarburg.com +49 40 3282-2631			
Sales Trading	rmueller@mmwarburg.com	Designated Sponsoring	sschulz@mmwarburg.com			
Bastian Quast	+49 40 3282-2701	Jörg Treptow	+49 40 3282-2658			
Sales Trading	bquast@mmwarburg.com	Designated Sponsoring	jtreptow@mmwarburg.com			
MACRO RESEARCH Carsten Klude	+49 40 3282-2572	Dr. Christian Jasperneite	+49 40 3282-2439			
Macro Research	cklude@mmwarburg.com	Investment Strategy	cjasperneite@mmwarburg.com			
Our research can be found under:						
Warburg Research	research.mmwarburg.com/en/index.html	Refinitiv	www.refinitiv.com			
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com			
FactSet	www.factset.com					
For access please conta	act:					
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703			
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com			